These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 10822428)

  • 1. The long-duration response to L-dopa in the treatment of early PD.
    Zappia M; Oliveri RL; Bosco D; Nicoletti G; Branca D; Caracciolo M; Napoli ID; Gambardella A; Quattrone A
    Neurology; 2000 May; 54(10):1910-5. PubMed ID: 10822428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to L-dopa in PD: the long and the short of it.
    Nutt JG
    Neurology; 2000 May; 54(10):1884-5. PubMed ID: 10822422
    [No Abstract]   [Full Text] [Related]  

  • 5. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
    Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
    Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.
    Waters CH; Nausieda P; Dzyak L; Spiegel J; Rudzinska M; Silver DE; Tsurkalenko ES; Kell S; Hsu A; Khanna S; Gupta S
    CNS Drugs; 2015 Apr; 29(4):341-50. PubMed ID: 25895021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.
    Ondo WG; Shinawi L; Moore S
    Mov Disord; 2010 Dec; 25(16):2724-7. PubMed ID: 20925074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [High dosage therapy of Parkinson disease. New dopamine agonist pramipexol allows reduction of L-dopa dose down to zero].
    Arnold G; Kupsch A
    Nervenarzt; 1999 Aug; 70(8):742-4. PubMed ID: 10483575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group.
    Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P
    Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
    Wolters EC; Horstink MW; Roos RA; Jansen EN
    Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Sciacca G; Mostile G; Disilvestro I; Donzuso G; Nicoletti A; Zappia M
    Mov Disord; 2023 Apr; 38(4):626-635. PubMed ID: 36840442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinson's Disease: Experience in Clinical Trials.
    Nausieda PA; Hsu A; Elmer L; Gil RA; Spiegel J; Singer C; Khanna S; Rubens R; Kell S; Modi NB; Gupta S
    J Parkinsons Dis; 2015; 5(4):837-45. PubMed ID: 26444090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are high doses of carbidopa a concern? A randomized, clinical trial in Parkinson's disease.
    Brod LS; Aldred JL; Nutt JG
    Mov Disord; 2012 May; 27(6):750-3. PubMed ID: 22508376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics of the long-duration response to levodopa in PD.
    Zappia M; Bosco D; Plastino M; Nicoletti G; Branca D; Oliveri RL; Aguglia U; Gambardella A; Quattrone A
    Neurology; 1999 Aug; 53(3):557-60. PubMed ID: 10449120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.
    Donzuso G; Sciacca G; Rascunà C; Cicero CE; Mostile G; Nicoletti A; Zappia M
    J Neurol; 2021 Nov; 268(11):4258-4264. PubMed ID: 33864515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.